Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group

• Published in: American journal of respiratory and critical care medicine Vol. 155; no. 1; p. 60
• Main Authors: Stansell, J D, Osmond, D H, Charlebois, E, LaVange, L, Wallace, J M, Alexander, B V, Glassroth, J, Kvale, P A, Rosen, M J, Reichman, L B, Turner, J R, Hopewell, P C
• Format: Journal Article
• Language: English
• Published: United States 01-01-1997
• Subjects: Adolescent; Adult; AIDS-Related Opportunistic Infections - diagnosis; AIDS-Related Opportunistic Infections - prevention & control; CD4 Lymphocyte Count; Female; HIV Infections - immunology; HIV Infections - physiopathology; Humans; Male; Middle Aged; Multivariate Analysis; Pneumonia, Pneumocystis - diagnosis; Pneumonia, Pneumocystis - prevention & control; Prospective Studies; Pulmonary Diffusing Capacity; Risk Factors
• ISSN: 1073-449X
• DOI: 10.1164/ajrccm.155.1.9001290

The Pulmonary Complications of HIV Infection Study is a prospective, multicenter, observational study evaluating pulmonary disease among HIV-infected persons. For approximately 52 mo, 1,182 HIV-infected subjects were followed. All participants were evaluated for pulmonary disease on a predetermined schedule. There were 145 episodes of Pneumocystis carinii pneumonia (PCP). Low CD4 count correlated with risk of PCP (p < 0.0001); 79% had CD4 counts less than 100/microl and 95% had CD4 counts less than 200/microl. Subtle changes in diffusing capacity for carbon monoxide (DLCO) were associated with PCP. Univariate analysis identified recurrent undiagnosed fevers, night sweats, oropharyngeal thrush, and unintentional weight loss to be associated with risk among persons with CD4 counts above 200/microl. Subjects in whom CD4 counts declined to below 200/microl and who were not receiving preventive therapy were nine times more likely to develop PCP within 6 mo compared with subjects who received such therapy. A strong trend toward differences between the sexes was detected. Black subjects had less than one third the risk of developing PCP as did white subjects (p < 0.0001). There was no significant difference in risk by HIV transmission category, study site, frequency of follow-up, age, education, smoking history, or use of antiretroviral therapy. Multivariable analysis revealed low CD4 lymphocyte count (p < 0.0001), use of prophylaxis (p < 0.0001), racial differences (p < 0.0001), and declining DLCO (p = 0.015) to influence risk. Constitutional signs and symptoms indicate increased risk for PCP among HIV-infected persons with CD4 counts above 200/microl.